Adult 200 mg (2 sachets) bid-tid. Childn 100 mg (1 sachet) bid-qid according to age. Duration: Acute phase: 5-10 days. Chronic state: May be continued for several mth.
Asthma; monitor patients w/ bronchial asthma during therapy. Discontinue treatment immediately if bronchospasm occur. Patient w/ history of peptic ulceration; histamine intolerance (long-term therapy). Concomitant administration of other medicines w/ known irritating effect on the gastric mucosa. Perform postural drainage & bronchoaspiration if patient is not able to effectively expectorate. Possible presence of sulfurous smell. Not to be mixed w/ other drugs. Contains sorbitol; not to be taken by patients w/ rare hereditary problems of fructose intolerance. Contains aspartame. May interfere w/ colorimetric assay method for salicylate measurement. May interfere w/ urine ketone test. Avoid use during or prior in pregnancy. Lactation.
Reduction in cough reflex that could lead to bronchial secretions accumulation w/ antitussive drugs. Significant hypotension & enhanced temporal artery dilation w/ nitroglycerin. May result in subtherapeutic levels of carbamazepine. Not recommended to be dissolved w/ other drugs. Inactivation of antibiotics. Reduced effect w/ activated charcoal.
R05CB01 - acetylcysteine ; Belongs to the class of mucolytics. Used in the treatment of wet cough. V03AB23 - acetylcysteine ; Belongs to the class of antidotes. Used to neutralize paracetamol overdose.
Sign Out
